Sasha J Vukelja

Suggest Changes
Learn More
516 Background: We assessed 10 menopausal symptoms at baseline and every 3 months during the first year of an ongoing randomized Phase III trial comparing relapse-free survival of postmenopausal(More)
3658 Background: Capecitabine (C) and irinotecan (I) have demonstrated to be effective against colorectal cancer. They have different antitumor mechanisms yet no cross-resistance. In this multicenter(More)
14550 Background: Pemetrexed has activity as a single agent and combined with gemcitabine (G) in platinum refractory metastatic urothelial cancer. The tolerability and activity of this new(More)
e13515 Background: P and PLD are clinically active as single agents and synergistic in preclinical models. This phase I, open-label trial determined the maximum tolerated dose (MTD) and safety(More)
500 Background: First results of study USON 01062 comparing adjuvant AC→T vs AC→XT in high-risk EBC [O'Shaughnessy, SABCS 2010] showed the primary endpoint, improvement in DFS, was not met (median FU(More)